Loading clinical trials...
Loading clinical trials...
This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Biogen
NCT07225504 · Secondary Progressive Multiple Sclerosis (SPMS)
NCT06599307 · Secondary Progressive Multiple Sclerosis (SPMS)
NCT04047628 · Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, and more
NCT04940065 · Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis
NCT05349474 · Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions